Published in Drug Week, December 21st, 2007
"Ten patients with mRCC (7m/3f; mean age, 63 yrs) were measured at baseline, 6-10 days after start of therapy (n=5, inhaled IL-2 only; n=5, inhaled IL-2 plus 1/11th of daily dose subcutaneously), and 16-29 days later under continuous combined...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.